This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lewis Phillips, G. D. Articles by Sliwkowski, M. X. Search for Related Content PubMed PubMed Citation Articles by Lewis Phillips, G. D. Articles by Sliwkowski, M. X.

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

¹ Genentech, Inc., South San Francisco, California and ² ImmunoGen, Inc., Waltham, Massachusetts

Requests for reprints: Gail D. Lewis Phillips, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. Phone: 650-225-2201; Fax: 650-225-1411; E-mail: gdl{at}gene.com or Mark X. Sliwkowski, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. Phone: 650-225-1247; Fax: 650-225-5770; E-mail: marks{at}gene.com.

Key Words: trastuzumab • DM1 • maytansinoid • antibody-drug conjugate • HER2

HER2 is a validated target in breast cancer therapy. Two drugs are currently approved for HER2-positive breast cancer: trastuzumab (Herceptin), introduced in 1998, and lapatinib (Tykerb), in 2007. Despite these advances, some patients progress through therapy and succumb to their disease. A variation on antibody-targeted therapy is utilization of antibodies to deliver cytotoxic agents specifically to antigen-expressing tumors. We determined in vitro and in vivo efficacy, pharmacokinetics, and toxicity of trastuzumab-maytansinoid (microtubule-depolymerizing agents) conjugates using disulfide and thioether linkers. Antiproliferative effects of trastuzumab-maytansinoid conjugates were evaluated on cultured normal and tumor cells. In vivo activity was determined in mouse breast cancer models, and toxicity was assessed in rats as measured by body weight loss. Surprisingly, trastuzumab linked to DM1 through a nonreducible thioether linkage (SMCC), displayed superior activity compared with unconjugated trastuzumab or trastuzumab linked to other maytansinoids through disulfide linkers. Serum concentrations of trastuzumab-MCC-DM1 remained elevated compared with other conjugates, and toxicity in rats was negligible compared with free DM1 or trastuzumab linked to DM1 through a reducible linker. Potent activity was observed on all HER2-overexpressing tumor cells, whereas nontransformed cells and tumor cell lines with normal HER2 expression were unaffected. In addition, trastuzumab-DM1 was active on HER2-overexpressing, trastuzumab-refractory tumors. In summary, trastuzumab-DM1 shows greater activity compared with nonconjugated trastuzumab while maintaining selectivity for HER2-overexpressing tumor cells. Because trastuzumab linked to DM1 through a nonreducible linker offers improved efficacy and pharmacokinetics and reduced toxicity over the reducible disulfide linkers evaluated, trastuzumab-MCC-DM1 was selected for clinical development. [Cancer Res 2008;68(22):9280–90]

This article has been cited by other articles:

				Y. Cao, J. D. Marks, J. W. Marks, L. H. Cheung, S. Kim, and M. G. Rosenblum Construction and Characterization of Novel, Recombinant Immunotoxins Targeting the Her2/neu Oncogene Product: In vitro and In vivo Studies Cancer Res., December 1, 2009; 69(23): 8987 - 8995. [Abstract] [Full Text] [PDF]

				S. V. Govindan, T. M. Cardillo, S.-J. Moon, H. J. Hansen, and D. M. Goldenberg CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates Clin. Cancer Res., October 1, 2009; 15(19): 6052 - 6061. [Abstract] [Full Text] [PDF]

				S. C. Alley, X. Zhang, N. M. Okeley, M. Anderson, C.-L. Law, P. D. Senter, and D. R. Benjamin The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 932 - 938. [Abstract] [Full Text] [PDF]

				J. Zha, C. O'Brien, H. Savage, L.-Y. Huw, F. Zhong, L. Berry, G. D. Lewis Phillips, E. Luis, G. Cavet, X. Hu, et al. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer Mol. Cancer Ther., August 1, 2009; 8(8): 2110 - 2121. [Abstract] [Full Text] [PDF]

				A. G. Polson and M. X. Sliwkowski Toward an Effective Targeted Chemotherapy for Multiple Myeloma Clin. Cancer Res., June 15, 2009; 15(12): 3906 - 3907. [Abstract] [Full Text] [PDF]